Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes.
about
A critical review of clinical trials for low-molecular-weight heparin therapy in unstable coronary artery diseaseAntithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysisXimelagatran: a new type of oral anticoagulant.Newer antithrombotic strategies in the initial management of non-ST-segment elevation acute coronary syndromes.Low molecular weight heparin in acute coronary syndromes.Risk stratification in non-ST segment elevation acute coronary syndromes with special focus on recent guidelines.Choice of agents to limit the coagulation cascade in acute coronary syndromes.Controlled continuous systemic heparinization increases success rate of artery-only anastomosis replantation in single distal digit amputation: A retrospective cohort studyNovel role for Sp1 in phorbol ester enhancement of human platelet thromboxane receptor gene expression.The therapeutic potential of novel anticoagulants.Thromboprophylaxis in hip arthroplasty. New frontiers and future strategy.A randomized clinical trial investigating the relationship between aprotinin and hypercoagulability in off-pump coronary surgery.Postoperative phlegmasia caerulea dolens: a case report and consideration of potential iatrogenic factors.Case studies in therapeutics: warfarin resistance and inefficacy in a man with recurrent thromboembolism, and anticoagulant-associated priapism.Perioperative management of aspirin resistance after off-pump coronary artery bypass grafting: possible role for aprotinin.Acenocoumarol associated priapism: report of a case.Prothrombin fragment 1.2 and modified antithrombin as predictors of disseminated intravascular coagulation and thrombotic risk in thermal injury.Lack of early augmentation of platelet reactivity after coronary intervention in patients treated with bivalirudin.Antithrombotic agents in the treatment of severe sepsis.Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease.Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action.Determinants of rebound thrombin activity after cessation of heparin in patients undergoing coronary interventions.Micro stent implantation in patients with acute myocardial infarction without anticoagulation: clinical experience with two different antithrombotic protocols.Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis.A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation.Late occurring clinical deep vein thrombosis in joint-operated patients.Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.
P2860
Q28186283-CFCEEF4D-2BF5-4702-A534-33894BDF1E41Q28187597-2F2E28C5-398E-4C01-9ECE-D4490D299408Q33226419-C5FEA4A5-6E7E-43BF-B420-9FEA29055003Q33838920-DE23DF1E-B9F7-4815-ABC7-888158337118Q34027303-9FBE55F8-D802-42DD-A4BA-DA2BC5145C7CQ34445660-63E5BC48-DD8E-47C0-8C60-0A40C51DF4EDQ34674164-B3D74760-E014-42E3-9CA2-644347614280Q37077911-FD4E6C4B-902C-4085-8BD6-E6DC5199DC16Q38354017-7A1F087A-E15D-402A-8BD8-B56ED258FC20Q40409337-EA899D60-ABCC-400D-88A1-3BB3DA124260Q40837295-335BD68A-B9BA-4756-B59F-C0B31605F695Q41850419-1A470F27-6225-4C14-961A-0922A810BD86Q41909806-C2EE2FD2-56D9-40FA-BEAF-F212EEADF6E4Q42000838-0C581D88-577A-4E05-8C13-8E26F00CE9A0Q43171003-7F619422-91F7-4A0C-BEE2-012F0DACBF8EQ44761455-BF9094C2-FD98-4CA5-9D28-19AC33486830Q45716686-755228D3-B3C7-456A-91FE-687049D5A23FQ46496796-A2A0B9EB-6C50-4C5C-9FC9-335E5A2E58E3Q46576624-C47E2B4A-1E1D-448F-AF78-31D221A6F8D6Q46765265-BA67D83A-2933-46EF-9E4F-AE5820B4E561Q47284848-FCC8DDF2-E393-4DDE-9396-4432CAA7C234Q47794645-D9FAA639-88E5-432F-9A03-1A6E8CADCDA9Q47937205-8296CF3B-6BB1-49D9-A857-6A6FD5B5B11EQ48006853-60C51628-96DE-4CA9-A32B-6DF6C33601BBQ50485303-7FE28F64-7F65-435B-AE57-43868001F461Q50658339-D10379FE-1F35-4CBE-AE92-DA4C1663CDD6Q53667550-4F3FA3C8-1AD7-4CAB-BD4B-7B00597781F0
P2860
Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Rebound increase in thrombin g ...... with acute coronary syndromes.
@en
Rebound increase in thrombin g ...... with acute coronary syndromes.
@nl
type
label
Rebound increase in thrombin g ...... with acute coronary syndromes.
@en
Rebound increase in thrombin g ...... with acute coronary syndromes.
@nl
prefLabel
Rebound increase in thrombin g ...... with acute coronary syndromes.
@en
Rebound increase in thrombin g ...... with acute coronary syndromes.
@nl
P2093
P356
P1433
P1476
Rebound increase in thrombin g ...... with acute coronary syndromes.
@en
P2093
Granger CB
Harrington RA
Krucoff MW
P304
P356
10.1161/01.CIR.91.7.1929
P407
P577
1995-04-01T00:00:00Z